50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention

Pathophysiology & Clinical Presentation of Chronic Coronary Disease

Chronic Coronary Disease (CCD), formerly termed Stable Ischemic Heart Disease (SIHD), is characterized by transient, reversible myocardial ischemia resulting from an imbalance between myocardial oxygen supply and myocardial oxygen demand ($MVO_2$).

Determinants of Myocardial Oxygen Dynamics

• Myocardial Oxygen Demand ($MVO_2$): Governed by three primary hemodynamic factors:
  1. Heart Rate: Tachycardia increases metabolic cycles per minute and shortens diastolic perfusion time;
  2. Myocardial Contractility (Inotropic State): Increased velocity and force of myocardial fiber shortening;
  3. Systolic Ventricular Wall Tension: Defined by Laplace's law ($Wall\ Tension = \frac{Pressure \times Radius}{2 \times Wall\ Thickness}$); driven by left ventricular afterload (systemic blood pressure) and preload (end-diastolic volume).
• Myocardial Oxygen Supply: Oxygen extraction by cardiac myocytes is near-maximal (~75%) even at rest. Consequently, any increase in oxygen demand must be met by an increase in coronary blood flow. Coronary perfusion occurs almost exclusively during diastole, because during systole, contracting ventricular myocardium compresses intramural coronary arterioles.
• Critical Stenosis Thresholds:
  • In healthy coronary arteries, autoregulatory arteriolar vasodilation can increase coronary blood flow up to four- to five-fold during exertion (coronary flow reserve).
  • When an atherosclerotic plaque narrows the luminal cross-sectional area by >=70% (or >=50% for the left main coronary artery), maximal downstream arteriolar vasodilation is exhausted at rest. Any exertional increase in $MVO_2$ induces transmural myocardial ischemia, precipitating angina.
  • At luminal stenosis >=90%, resting blood flow is impaired, predisposing to ischemia even at rest.

Clinical Classification of Chest Discomfort: Diamond-Forrester Criteria

The Diamond-Forrester clinical classification remains the foundational tool for stratifying chest discomfort and estimating pre-test probability:

                  DIAMOND-FORRESTER CLASSIFICATION OF CHEST PAIN

   Classification      Definition & Diagnostic Criteria
   ═════════════════════════════════════════════════════════════════════════════════════════
   Typical Angina      Meets ALL THREE of the following cardinal clinical criteria:
   (Definite)          1. Substernal chest discomfort with characteristic quality (pressure,
                          squeezing, heaviness, tightness) and duration (2 to 10 minutes);
                       2. Provoked by physical exertion or emotional / psychological stress;
                       3. Promptly relieved by rest OR sublingual nitroglycerin within 5 min.

   Atypical Angina     Meets EXACTLY TWO of the three cardinal criteria above.
   (Probable)          (Frequently encountered in women, elderly patients, and diabetics).

   Non-Cardiac Pain    Meets ZERO or ONLY ONE of the three cardinal criteria above.
                       (Suggests musculoskeletal, gastrointestinal, or pulmonary etiologies).
   ═════════════════════════════════════════════════════════════════════════════════════════

• Anginal Equivalents: Vulnerable demographic cohorts—particularly women, older adults (>=75 years), and individuals with longstanding diabetes mellitus—frequently present without classic substernal pressure. Instead, they manifest "anginal equivalents": new or worsening exertional dyspnea, unexplained extreme fatigue, diaphoresis, epigastric burning, nausea, or presyncope. In diabetics, autonomic cardiac neuropathy blunts visceral nociceptive transmission, permitting silent myocardial ischemia and delayed presentation.

Diagnostic Testing Cascade: Pre-Test Probability & Modality Selection

The diagnostic evaluation of suspected chronic coronary disease begins with calculating the patient's pre-test probability (PTP) based on age, biological sex, and chest pain classification (typical, atypical, or non-cardiac). Patients with very low PTP (<5%) generally require no cardiac testing, whereas those with intermediate (5% to 85%) or high (>85%) PTP require non-invasive functional or anatomical imaging.

                  NON-INVASIVE DIAGNOSTIC TESTING MODALITIES

   Modality              Key Patient Indications                       Major Contraindications / Limitations
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Exercise Treadmill    Able to exercise (>=5 METs, achieve           Uninterpretable baseline resting ECG:
   ECG Testing (TMT)     >=85% max predicted HR); normal baseline      LBBB, paced rhythm, ST depression >1 mm,
                         resting ECG; intermediate PTP                 WPW pre-excitation, digitalis use.

   Exercise Stress       Normal or abnormal resting ECG; able to       Poor acoustic windows (severe COPD, severe
   Echocardiography      exercise; assesses regional wall motion       obesity); cannot exercise.

   Pharmacologic Stress  Unable to exercise (amputee, severe OA,       Severe active reactive airway disease / asthma
   Scintigraphy (SPECT/  frailty); abnormal baseline ECG; assesses     (contraindicates adenosine/regadenoson);
   PET Perfusion)        myocardial perfusion & viability              caffeine/theophylline within 12-24 hours.

   Dobutamine Stress     Unable to exercise; contraindication to       Severe ventricular arrhythmias, severe
   Echocardiography      vasodilators (severe reactive airway disease) hypertension (>220/120 mmHg), recent ACS.

   Coronary CT           Low-to-intermediate PTP; high negative        Severe extensive coronary calcification
   Angiography (CCTA)    predictive value (>98%); assesses anatomical  (Agatston calcium score >1000); renal failure
                         plaque burden and luminal stenosis            (contrast); irregular heart rhythms (atrial fib).
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Non-Invasive Testing Modality Selection

1. Exercise Treadmill ECG Testing (Standard Bruce Protocol):
   • Preferred initial test in patients who are fully capable of physical exercise (can achieve >=5 metabolic equivalents [METs], such as climbing two flights of stairs or walking briskly up a hill) and possess an interpretable baseline resting ECG.
   • Diagnostic Positivity: Horizontal or downsloping ST-segment depression of >=1.0 mm (0.1 mV) measured 80 milliseconds past the J-point during or immediately following exercise.
   • The Uninterpretable ECG Rule: Exercise treadmill ECG testing without imaging is completely non-diagnostic if the baseline ECG displays: Left Bundle Branch Block (LBBB), ventricular paced rhythm, pre-excitation (Wolff-Parkinson-White syndrome), baseline ST-segment depression >1.0 mm (e.g., from severe LVH with strain), or digoxin effect. These patients must undergo imaging (stress echocardiography or nuclear perfusion scintigraphy).
2. Pharmacologic Vasodilator Stress Testing (Regadenoson, Adenosine, Dipyridamole):
   • Indicated in patients physically unable to exercise.
   • Mechanism: Selective coronary arteriolar vasodilators (adenosine A2A receptor agonists) produce maximal hyperemia in healthy coronary arteries, increasing blood flow four- to five-fold. Diseased coronary arteries with fixed stenoses cannot vasodilate further. This creates a relative disparity in blood flow ("coronary steal"), visualized on SPECT or PET myocardial perfusion imaging as a reversible perfusion defect.
   • Contraindications & Precautions: Strictly contraindicated in patients with active, severe bronchospastic airway disease (asthma with wheezing) because adenosine A2B/A3 receptor activation can trigger fatal bronchospasm. Patients must abstain from caffeine, theophylline, and methylxanthines for 12 to 24 hours prior to testing, as these compounds competitively antagonize adenosine receptors and cause false-negative scans.
3. Coronary Computed Tomographic Angiography (CCTA):
   • CCTA provides non-invasive anatomical visualization of the coronary lumen and vessel wall, boasting an exceptional negative predictive value exceeding 98%.
   • Endorsed by ACC/AHA guidelines as an outstanding first-line test for low-to-intermediate risk patients presenting with stable chest pain: a normal CCTA reliably excludes obstructive coronary disease and portends an excellent long-term prognosis, safely obviating downstream invasive testing.

Medical Antianginal Therapy & The Nitrate Tolerance Phenomenon

Medical management of chronic stable angina aims to alleviate symptoms, prevent exercise-induced ischemia, and improve quality of life. Guidelines emphasize a stepwise pharmacologic approach:

                  STEPWISE MEDICAL ANTIANGINAL PHARMACOTHERAPY

   Therapeutic Line      Drug Class & Specific Agents                  Hemodynamic Effects & Mechanism
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   First-Line Antianginal Beta-Blockers:                              Decreases HR, contractility, and SBP;
                         Metoprolol succinate, Carvedilol, Atenolol    lowers MVO2; lengthens diastolic filling time;
                         (Titrate to resting HR 55 to 60 bpm)          mortality benefit in post-MI and HFrEF.

   Second-Line Add-On    Dihydropyridine CCBs:                         Arteriolar vasodilation reduces afterload;
   or Alternative        Amlodipine (5-10 mg), Felodipine              coronary vasodilation; synergistic with BB.

                         Non-Dihydropyridine CCBs:                     Lowers HR and contractility; alternative if BB
                         Diltiazem, Verapamil                          contraindicated; AVOID in HFrEF.

                         Long-Acting Nitrates:                         Venodilation reduces preload (LVEDP and wall
                         Isosorbide mononitrate ER (30-120 mg)         stress); requires 10-14h daily nitrate-free interval.

   Third-Line /          Ranolazine                                    Selective late sodium current (INa) inhibitor;
   Refractory Angina     (500 to 1,000 mg twice daily)                 reduces intracellular Ca2+ overload and diastolic
                                                                       wall tension; NO EFFECT on HR or BP.
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Pharmacologic Mechanics & Safety Mandates

• First-Line Beta-Blockade: Beta-blockers are the undisputed first-line antianginal agents in patients without contraindications. By competitively inhibiting cardiac beta-1 adrenergic receptors, they reduce resting and exercise-induced heart rate and myocardial contractility, directly diminishing $MVO_2$. The clinical dosing target is a resting heart rate of 55 to 60 beats per minute, with an exercise heart rate not exceeding 100 beats per minute.
• Long-Acting Nitrates & The Nitrate-Free Interval:
  • Nitrates undergo intracellular metabolic bioactivation via mitochondrial aldehyde dehydrogenase (ALDH-2) to release nitric oxide (NO), stimulating soluble guanylate cyclase and generating cyclic guanosine monophosphate (cGMP). The resulting smooth muscle relaxation predominantly dilates large capacitance systemic veins, reducing venous return (preload), left ventricular end-diastolic pressure, and intramyocardial wall tension.
  • The Nitrate Tolerance Phenomenon: Continuous round-the-clock exposure to nitrates leads to rapid development of tolerance (tachyphylaxis) within 24 to 48 hours, rendering the drug completely ineffective. This is driven by depletion of intracellular sulfhydryl donors, uncoupling of endothelial nitric oxide synthase, and neurohormonal reflex activation.
  • The Mandate: To preserve antianginal efficacy, all long-acting nitrate regimens (oral isosorbide mononitrate or transdermal nitroglycerin patches) must incorporate a daily 10- to 14-hour nitrate-free interval (e.g., administering once-daily extended-release isosorbide mononitrate in the morning, or removing transdermal patches at bedtime).

[!CAUTION] THE ABSOLUTE CONTRAINDICATION: NITRATES & PDE-5 INHIBITORS Concurrent administration of any nitrate formulation (sublingual nitroglycerin, long-acting isosorbide mononitrate/dinitrate) with phosphodiesterase-5 (PDE-5) inhibitors (sildenafil, vardenafil, tadalafil) is STRICTLY CONTRAINDICATED.

Nitrates stimulate cGMP production, while PDE-5 inhibitors block cGMP degradation. Co-administration causes massive, unchecked cGMP accumulation in vascular smooth muscle, triggering catastrophic, refractory vasodilation, profound hypotension, coronary hypoperfusion, and fatal cardiac arrest.

Nitrates must be withheld for at least 24 hours after the last dose of sildenafil or vardenafil, and for at least 48 hours after the last dose of tadalafil (due to its extended 17.5-hour half-life).

• Ranolazine Mechanics:
  • Ranolazine selectively inhibits the late inward sodium current ($I_{Na}$) during myocardial repolarization. In ischemic myocytes, excess late sodium entry leads to reverse operation of the sodium-calcium exchanger ($NCX$), producing pathological intracellular calcium overload, impaired diastolic relaxation, and microvascular compression.
  • By blocking this sodium influx, ranolazine decreases intracellular calcium, improves diastolic compliance, and enhances subendocardial perfusion WITHOUT affecting heart rate, blood pressure, or inotropy. It is particularly valuable in patients limited by bradycardia or borderline hypotension. It causes dose-dependent prolongation of the QTc interval, necessitating baseline and follow-up ECG monitoring.

Post-MI / Post-PCI Secondary Prevention: The "Fantastic Four" Bundle

Following acute myocardial infarction (STEMI or NSTEMI) and percutaneous coronary intervention (PCI) with drug-eluting stents (DES), long-term management is focused on aggressive secondary prevention to prevent stent thrombosis, recurrent infarction, adverse ventricular remodeling, and cardiovascular death. Guideline consensus mandates the immediate initiation of the "Fantastic Four" secondary prevention bundle:

                  THE POST-MI SECONDARY PREVENTION "FANTASTIC FOUR"

   Pillar                Specific Guideline Regimen                    Mechanisms & Clinical Targets
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   1. Dual Antiplatelet  Aspirin 81 mg daily INDEFINITELY              Inhibits COX-1 thromboxane A2;
      Therapy (DAPT)     PLUS Ticagrelor 90 mg BID (or Prasugrel       Inhibits P2Y12 ADP platelet receptor;
                         10 mg daily) for a MINIMUM OF 12 MONTHS       prevents acute stent thrombosis.

   2. High-Intensity     Atorvastatin 80 mg daily (or 40 mg)           Plaque stabilization, anti-inflammatory;
      Statin Therapy     OR Rosuvastatin 20 to 40 mg daily             Target LDL-C reduction >=50% AND
                         INDEFINITELY for all post-MI patients         absolute LDL-C < 55 to 70 mg/dL.

   3. Beta-Blocker       Evidence-based agents:                        Reduces ventricular arrhythmogenesis & MVO2;
      Therapy            Carvedilol, Metoprolol succinate, Bisoprolol  Minimum 1 to 3 years if LVEF normal;
                         titrated to resting HR 55-60 bpm              INDEFINITELY if LVEF <= 40%.

   4. ACE Inhibitor      Lisinopril, Ramipril, or Enalapril            Inhibits RAAS-mediated adverse ventricular
      or ARB             (ARBs: Losartan, Valsartan if ACEi intolerant) remodeling; indicated in LVEF <= 40%,
                                                                       hypertension, diabetes mellitus, or CKD.
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Clinical Nuances of Post-MI Pharmacotherapy

1. Dual Antiplatelet Therapy (DAPT):
   • P2Y12 Inhibitor Selection: In the post-ACS/PCI setting, Ticagrelor (90 mg twice daily) or Prasugrel (10 mg daily) is strongly preferred over Clopidogrel (75 mg daily) based on the landmark PLATO and TRITON-TIMI 38 trials, which demonstrated significant reductions in ischemic death, recurrent MI, and stent thrombosis.
   • Prasugrel Contraindications: Prasugrel is STRICTLY CONTRAINDICATED in patients with a history of stroke or transient ischemic attack (TIA) due to a significant increase in fatal intracranial hemorrhage. It is also generally avoided in patients aged >=75 years or weighing <60 kg.
   • Ticagrelor Nuances: Ticagrelor causes a reversible, non-bronchospastic dyspnea in 10% to 15% of patients (mediated by inhibition of cellular adenosine reuptake) that typically resolves over several weeks without causing heart failure or pulmonary injury. Maintenance aspirin doses combined with ticagrelor must not exceed 81 mg daily, as higher aspirin doses (>100 mg) significantly attenuate ticagrelor's clinical efficacy.
   • Duration: Minimum duration of DAPT is 12 months post-ACS regardless of stent type, after which P2Y12 therapy is discontinued and aspirin 81 mg daily is continued indefinitely.
2. High-Intensity Statin & Non-Statin Escalation:
   • All post-MI patients require immediate, high-intensity statin therapy regardless of their baseline LDL-C level.
   • Targets: Achieve >=50% reduction in baseline LDL-C AND achieve an absolute LDL-C <70 mg/dL (with modern ACC/AHA and European guidelines advocating an even stricter target of <55 mg/dL for very high-risk ASCVD).
   • Non-Statin Add-On Therapy:
     • Recheck fasting lipid panel 4 to 12 weeks post-MI.
     • If LDL-C remains >=70 mg/dL despite maximally tolerated high-intensity statin therapy, add Ezetimibe 10 mg daily (supported by the IMPROVE-IT trial, showing significant further reduction in recurrent cardiovascular events).
     • If LDL-C remains >=70 mg/dL on maximally tolerated statin plus ezetimibe in very high-risk patients, add a PCSK9 inhibitor (evolocumab or alirocumab subcutaneously every 2-4 weeks; supported by the FOURIER and ODYSSEY Outcomes trials).
3. Beta-Blocker Duration:
   • Post-MI patients with reduced LV systolic function (LVEF <=40%) must continue an evidence-based beta-blocker (carvedilol, metoprolol succinate, bisoprolol) indefinitely to prevent sudden cardiac death and heart failure progression.
   • In post-MI patients with preserved LV function (LVEF >50%) who have undergone successful revascularization and lack persistent angina or arrhythmias, current guidelines recommend continuing beta-blocker therapy for at least 1 to 3 years, after which reassessment and potential de-escalation may be considered.

Critical Post-MI Interventions: Cardiac Rehab & Vaccinations

• Comprehensive Outpatient Cardiac Rehabilitation:
  • A structured, multidisciplinary outpatient program comprising medically monitored aerobic exercise training, cardiovascular risk factor reduction, nutritional education, and psychosocial counseling.
  • Class 1A Guideline Recommendation: Participation in cardiac rehabilitation confers a 25% relative reduction in all-cause mortality, lowers recurrent hospitalizations, and improves functional capacity. Every post-MI patient must be formally referred prior to hospital discharge.
• Preventive Immunizations:
  • Annual Inactivated Influenza Vaccination: Acute influenza infection triggers severe systemic inflammation, sympathetic surge, and prothrombotic cascades that precipitate acute coronary plaque rupture. Landmark randomized clinical trials (such as the IAMI trial) demonstrate that receiving an influenza vaccine immediately post-MI reduces all-cause mortality and secondary cardiovascular composite events by 18% to 28%.
  • Pneumococcal Vaccination: Post-MI patients should receive pneumococcal immunization (PCV20 alone or PCV15 followed by PPSV23) to prevent bacteremic pneumococcal pneumonia.